fenofibrate has been researched along with Muscle Disorders in 16 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypothyroidism is one of the common causes of the secondary hypercholesterolemia." | 6.43 | [Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature]. ( Brzosko, M; Lukjanowicz, M; Trzcińska-Butkiewicz, B, 2006) |
| "Hypothyroidism is one of the common causes of the secondary hypercholesterolemia." | 2.43 | [Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature]. ( Brzosko, M; Lukjanowicz, M; Trzcińska-Butkiewicz, B, 2006) |
| "Fenofibrate (FEN) is an antilipidemic drug that increases the activity of the lipoprotein lipase enzyme, thus enhancing lipolysis; however, it may cause myopathy and rhabdomyolysis in humans." | 1.91 | Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle? ( AbdElfattah, AA; Ayuob, NN; El-Bassouny, DR; Ellakkany, AS; Mansour, AA, 2023) |
| " Interactions between statins and other drugs are caused by pharmacokinetic mechanisms, mainly by changing the metabolism of statins in the CYP450 enzyme system, in the hepatic glucuronidation pathway or in the transporters responsible for statin distribution in tissues." | 1.40 | [The combinations of statins and fibrates: pharmacokinetic and clinical implications]. ( González Santos, P, 2014) |
| " We reviewed gemfibrozil- and fenofibrate-associated adverse event reports (AERs) submitted to the US Food and Drug Administration over a 5-year period." | 1.35 | Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. ( Alsheikh-Ali, AA; Holoshitz, N; Karas, RH, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (12.50) | 18.7374 |
| 1990's | 1 (6.25) | 18.2507 |
| 2000's | 9 (56.25) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| El-Bassouny, DR | 1 |
| Mansour, AA | 1 |
| Ellakkany, AS | 1 |
| Ayuob, NN | 1 |
| AbdElfattah, AA | 1 |
| Streja, E | 1 |
| Streja, DA | 1 |
| Soohoo, M | 1 |
| Kleine, CE | 1 |
| Hsiung, JT | 1 |
| Park, C | 1 |
| Moradi, H | 1 |
| González Santos, P | 1 |
| Robinson, JG | 1 |
| Pettersen, JC | 1 |
| Pruimboom-Brees, I | 1 |
| Francone, OL | 1 |
| Amacher, DE | 1 |
| Boldt, SE | 1 |
| Kerlin, RL | 1 |
| Ballinger, WE | 1 |
| Ghosh, B | 1 |
| Sengupta, S | 1 |
| Bhattacharjee, B | 1 |
| Majumder, A | 1 |
| Sarkar, SB | 1 |
| Grundy, SM | 1 |
| Vega, GL | 1 |
| Yuan, Z | 1 |
| Battisti, WP | 1 |
| Brady, WE | 1 |
| Palmisano, J | 1 |
| Ledl, M | 1 |
| Hohenecker, J | 1 |
| Francesconi, C | 1 |
| Roots, I | 1 |
| Bauer, MF | 1 |
| Roden, M | 1 |
| Pierno, S | 1 |
| Didonna, MP | 1 |
| Cippone, V | 1 |
| De Luca, A | 1 |
| Pisoni, M | 1 |
| Frigeri, A | 1 |
| Nicchia, GP | 1 |
| Svelto, M | 1 |
| Chiesa, G | 1 |
| Sirtori, C | 1 |
| Scanziani, E | 1 |
| Rizzo, C | 1 |
| De Vito, D | 1 |
| Conte Camerino, D | 1 |
| Lukjanowicz, M | 1 |
| Trzcińska-Butkiewicz, B | 1 |
| Brzosko, M | 1 |
| Dedhia, V | 1 |
| Munsi, SC | 1 |
| Holoshitz, N | 1 |
| Alsheikh-Ali, AA | 1 |
| Karas, RH | 1 |
| Giraud, P | 1 |
| Cassou, M | 1 |
| Paul, R | 1 |
| Guidet, M | 1 |
| Solsona, L | 1 |
| Coll, J | 1 |
| Ariza, A | 1 |
| Olivé, A | 1 |
| Muller, JP | 1 |
| Mazingue, A | 1 |
| Cotes, F | 1 |
| Destée, A | 1 |
| Warot, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| FEnofibRate as a Metabolic INtervention for Coronavirus Disease 2019[NCT04517396] | Phase 2 | 701 participants (Actual) | Interventional | 2020-08-18 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Parallel Group Study to Evaluate the Tolerability and Efficacy of the Co-Administration of Simvastatin 20 mg/Day and Fenofibrate 160 mg/Day Compared to Simvastatin 20 mg/Day Alone for 12 Weeks of Treatment in Patie[NCT00092157] | Phase 3 | 571 participants (Actual) | Interventional | 2002-05-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Death from any cause during the observation period (NCT04517396)
Timeframe: Up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Fenofibrate + Usual Care | 19 |
| Placebo + Usual Care | 22 |
The exploratory global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) The number of days out of the hospital during the 30 day-period following randomization. (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.03 |
| Placebo + Usual Care | 5.03 |
Number of days that participants were alive and out of the hospital during the 30 days following randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Median) |
|---|---|
| Fenofibrate + Usual Care | 30 |
| Placebo + Usual Care | 30 |
Number of days participants were alive, out of the intensive care unit, free of mechanical ventilation/extracorporeal membrane oxygenation, or maximal available respiratory support during the 30 days that followed randomization (NCT04517396)
Timeframe: Up to 30 days
| Intervention | days (Mean) |
|---|---|
| Fenofibrate + Usual Care | 28.8 |
| Placebo + Usual Care | 28.3 |
The primary endpoint of the trial is a global rank score that ranks patient outcomes according to 5 factors. The global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, the modified Borg dyspnea scale (NCT04517396)
Timeframe: 30 days
| Intervention | Ranked Severity Score (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.32 |
| Placebo + Usual Care | 5.33 |
The secondary global rank score, or global severity score, is a nonparametric, hierarchically ranked outcome. The global rank score was generated by ranking all 701 participants on a scale of 1 to 701, from worst to best clinical outcomes. Participants were ranked by (1) time to death; (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); (3) The inspired concentration of oxygen/percent oxygen saturation (FiO2/SpO2) ratio area under the curve; (4) For participants enrolled as outpatients who are subsequently hospitalized, the number of days out of the hospital during the 30 day-period following randomization; (5) For participants enrolled as outpatients who don't get hospitalized during the 30-day observation period, a COVID-19 symptom scale rating fever, cough, dyspnea, muscle aches, sore throat, loss of smell or taste, headache, diarrhea, fatigue, nausea/vomiting, chest pain (each are rated from 0-10 then summed). (NCT04517396)
Timeframe: Up to 30 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 5.05 |
| Placebo + Usual Care | 5.05 |
A seven-category ordinal scale consisting of the following categories: 1, not hospitalized with resumption of normal activities; 2, not hospitalized, but unable to resume normal activities; 3, hospitalized, not requiring supplemental oxygen; 4, hospitalized, requiring supplemental oxygen; 5, hospitalized, requiring nasal high-flow oxygen therapy, noninvasive mechanical ventilation, or both; 6, hospitalized, requiring extracorporeal membrane oxygenation (ECMO), invasive mechanical ventilation, or both; and 7, death. (NCT04517396)
Timeframe: At 15 days
| Intervention | score on a scale (Median) |
|---|---|
| Fenofibrate + Usual Care | 1 |
| Placebo + Usual Care | 1 |
3 reviews available for fenofibrate and Muscle Disorders
| Article | Year |
|---|---|
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hy | 2018 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron | 2008 |
[Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature].
Topics: Contraindications; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Male; | 2006 |
1 trial available for fenofibrate and Muscle Disorders
| Article | Year |
|---|---|
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Topics: Adult; Aged; Alanine Transaminase; Apolipoproteins; Aspartate Aminotransferases; Double-Blind Method | 2005 |
12 other studies available for fenofibrate and Muscle Disorders
| Article | Year |
|---|---|
Can coenzyme Q10 alleviate the toxic effect of fenofibrate on skeletal muscle?
Topics: Adult; Animals; Fenofibrate; Humans; Male; Muscle Fibers, Skeletal; Muscle, Skeletal; Muscular Disea | 2023 |
[The combinations of statins and fibrates: pharmacokinetic and clinical implications].
Topics: Atherosclerosis; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fibric Ac | 2014 |
The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat.
Topics: Animals; Blood Chemical Analysis; Body Weight; Dose-Response Relationship, Drug; Female; Fenofibrate | 2012 |
Fenofibrate-induced myopathy.
Topics: Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Middle Aged; Muscular Diseases | 2004 |
Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.
Topics: Aged; Creatine Kinase; Diabetes Mellitus, Type 2; Drug Interactions; Electromyography; Fenofibrate; | 2005 |
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.
Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response | 2006 |
Myopathy caused by a combination rosuvastatin and fenofibrate.
Topics: Aged; Coronary Artery Disease; Drug Interactions; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethyl | 2007 |
Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.
Topics: Adverse Drug Reaction Reporting Systems; Chemical and Drug Induced Liver Injury; Databases, Factual; | 2008 |
[Muscular toxicity due to fenofibrate. Apropos of a case].
Topics: Aged; Female; Fenofibrate; Humans; Hypolipidemic Agents; Muscular Diseases; Propionates | 1982 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Intera | 2001 |
[Myopathy caused by fenofibrate].
Topics: Aged; Aged, 80 and over; Female; Fenofibrate; Humans; Muscles; Muscular Diseases; Pain | 1991 |
[Muscular toxicity caused by fenofibrate].
Topics: Female; Fenofibrate; Humans; Middle Aged; Muscular Diseases; Propionates | 1989 |